Global Longlife Hospital and Research Ltd vs Sun Pharmaceutical Industries Ltd

A side-by-side comparison of Global Longlife Hospital and Research Ltd (GLHRL) and Sun Pharmaceutical Industries Ltd (SUNPHARMA) — valuation, profitability, growth, and financial health — to help you judge which is the stronger buy today.

The verdict

On the numbers, Sun Pharmaceutical Industries Ltd leads GLHRL vs SUNPHARMA on 9 of 14 metrics (2 tied). See the breakdown below — the right pick still depends on your goals (value vs growth, risk appetite).

Valuation

How expensive each stock is relative to its earnings and book value. Lower usually means cheaper.

65.21
P/E ratio
41.01
0.52
P/B ratio
5.60
0.00%
Dividend yield
0.82%
₹0.19
EPS
₹47.84

Profitability

How efficiently each company turns capital and sales into profit. Higher is better.

-6.81%
Return on equity
16.00%
-13.69%
Return on capital
21.00%
0.00%
EBITDA margin
30.00%
64.52%
Net margin
19.69%

Growth

Three-year compounded growth. Faster-growing businesses can justify a higher valuation.

Revenue CAGR (3Y)
10.03%
Profit CAGR (3Y)
10.57%

Size & financial health

Scale and balance-sheet strength. Bigger revenue/profit and lower debt are generally safer.

₹13 Cr
Market cap
₹4.67L Cr
₹0 Cr
Revenue
₹58,462 Cr
₹0 Cr
Net profit
₹11,509 Cr
0.00
Debt / equity
0.06
Global Longlife Hospital and Research Ltd
  • + ["Company is almost debt free.", "Stock is trading at 0.52 times its book value"]
  • ["Company has low interest coverage ratio.", "Promoter holding has decreased over last quarter: -12.6%", "Promoter holding is low: 22.9%", "Company has a low return on equity of -8.85% over last 3 years."]
Sun Pharmaceutical Industries Ltd
  • + ["Company is almost debt free.", "Company has been maintaining a healthy dividend payout of 34.1%"]
  • ["The company has delivered a poor sales growth of 11.8% over past five years."]
Global Longlife Hospital and Research Ltd full analysis Sun Pharmaceutical Industries Ltd full analysis

This comparison is for informational purposes only and is not investment advice. Please consult a SEBI-registered advisor before investing.